Health and Wellness

NAMS calls for cancer to be declared notifiable disease, backs indigenous HPV test and vaccine rollout

Published by
Saurav Gupta

The National Academy of Medical Sciences (NAMS) has called for cancer to be classified as a notifiable disease and expects the upcoming inclusion of indigenous HPV tests and vaccines in the national health programme to significantly enhance cancer prevention and treatment.

During its 65th foundation day on Monday, NAMS highlighted key findings from its task force on cervical and breast cancer, stressing the need for robust data collection to inform health surveillance and policy decisions.

Officials underscored that women over 30 should undergo regular cancer screening, pointing to low current coverage rates.

Dr Neerja Bhatla, professor and former head of Obstetrics and Gynaecology at All India Institute of Medical Sciences (AIIMS), vice president of NAMS, and founding head of the WHO Collaborating Centre for Cervical Cancer Prevention at AIIMS, spoke about the state of cervical cancer testing in India.

Also read: A Delhi doctor’s self-exam protocol for early breast cancer detection

Dr Bhatla noted that although HPV testing is the main diagnostic method, its cost has spurred the development of more affordable local alternatives. These tests, suitable for primary care centres and requiring minimal training, are expected to be integrated into national efforts.

She added that these cost-effective, validated HPV tests—which target fewer genotypes—are now available and compatible with portable equipment, allowing for same-day screening and treatment.

Regarding vaccinations, Health Minister JP Nadda had informed the Lok Sabha last August that the National Technical Advisory Group on Immunisation had recommended introducing the HPV vaccine into the national immunisation schedule.

However, issues around dosage (single vs double) and implementation logistics remain. While external experts back a single-dose regimen, the government must ensure readiness for rollout.

Indigenous single-dose HPV vaccine trials are currently underway, with interim findings expected by 2026 and final data by 2027.

Also read: Closure of mohalla clinics sparks fear and anger in Delhi

Dr Bhatla also claimed that if an individual is vaccinated at the age of 15, then cervical cancer cases can be prevented by 80%.

Saurav Gupta

With nearly six years of experience as a journalist, he has written extensively on developmental issues, policies, health, and government agency schemes across both print and digital platforms. He holds a BAJMC degree from IP University.

Published by
Saurav Gupta
Tags: cancer

Recent Posts

Beer sales up 10% in Delhi this May as popular brands regain shelf space: Excise data

According to data, the share of well-known national beer brands increased to 54 per cent…

June 13, 2026

Sunny morning in Delhi, rain likely

The India Meteorological Department (IMD) has forecast thunderstorms accompanied by rain and gusty winds on…

June 13, 2026

Pamela Mountbatten and her enduring ties with Delhi

Present in Delhi on the night of India’s Independence, the daughter of India's last viceroy…

June 13, 2026

Prince Yadav: After Virender Sehwag, Najafgarh sends another cricketer to Team India

Prince Yadav's journey from tennis-ball cricket to dismissing Virat Kohli in the IPL has culminated…

June 12, 2026

Delhi HC issues notice on Salman Khan’s plea for stay on release of ‘Kala Hiran’

Delhi High Court seeks response from makers of "Kala Hiran: The Battle for Legal" on…

June 12, 2026

Delhi: Leopard sightings surge in Asola Bhatti sanctuary

Leopard sightings are increasing in Delhi's Asola Bhatti Wildlife Sanctuary, with officials attributing the trend…

June 12, 2026